TransMedics Group (NASDAQ:TMDX) Downgraded by Wall Street Zen to Hold

Key Points

• TransMedics Group has been downgraded from a "buy" to a "hold" rating by analysts at Wall Street Zen, indicating a shift in market sentiment towards the stock.
• Despite the downgrade, analysts such as Piper Sandler and Oppenheimer have set target prices that reflect a potential upside, with Oppenheimer increasing its price target from $130.00 to $150.00.
• TransMedics reported strong financial performance with a 37.7% year-over-year revenue increase in its latest quarterly earnings, exceeding analyst expectations in both earnings per share and revenue.

Wall Street Zen lowered shares of TransMedics Group (NASDAQ:TMDX - Free Report) from a buy rating to a hold rating in a research report report published on Saturday morning.

Other research analysts also recently issued research reports about the stock. Morgan Stanley raised their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Finally, Canaccord Genuity Group raised their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, TransMedics Group currently has an average rating of "Moderate Buy" and an average target price of $123.00.

TransMedics Group Trading Down 1.5%

TMDX stock traded down $1.76 during trading on Friday, hitting $114.96. The company had a trading volume of 665,581 shares, compared to its average volume of 942,848. The firm has a market capitalization of $3.92 billion, a P/E ratio of 59.57 and a beta of 2.18. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $172.78. The company has a 50 day simple moving average of $119.99 and a 200-day simple moving average of $103.59. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.00% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

Institutional investors have recently bought and sold shares of the stock. NBC Securities Inc. acquired a new stake in TransMedics Group in the 1st quarter worth approximately $25,000. Opal Wealth Advisors LLC acquired a new stake in TransMedics Group during the 2nd quarter valued at approximately $26,000. Smartleaf Asset Management LLC lifted its stake in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after acquiring an additional 135 shares during the period. Quarry LP lifted its stake in TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after acquiring an additional 278 shares during the period. Finally, Sound Income Strategies LLC acquired a new stake in TransMedics Group during the 2nd quarter valued at approximately $48,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.